New eye drug hopes to slow inherited blindness

NCT ID NCT06970106

First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 33 times

Summary

This early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules in about 18 adults from Australia, New Zealand, and other APAC countries. Researchers will also look at whether the treatment can help preserve or improve vision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPA1 GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cerulea Clinical Trials

    RECRUITING

    East Melbourne, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Retina Specialists

    RECRUITING

    Auckland, 1052, New Zealand

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Save Sight Institute - Sydney Eye Hospital

    RECRUITING

    Sydney, New South Wales, 2000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.